文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

转移性黑色素瘤脑转移全脑放疗的单中心结局

Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.
PubMed 文献 · Radiat Oncol · 2021-02-08

本文回顾性分析单中心2000—2018年接受全脑放疗(WBRT)的63例黑色素瘤脑转移(MBM)患者,中位WBRT剂量为30 Gy/10次,中位随访4.0个月。患者中位总生存(OS)为7.0个月,体能状态与OS相关,BRAF抑制剂是唯一显著影响OS的全身治疗。

要点

  • MBM患者WBRT后中位OS为7.0个月,中位无进展生存(PFS)为2.2个月。
  • BRAF抑制剂与OS改善显著相关(HR 0.24,95%CI 0.07-0.79,p=0.019)。
  • 可评估影像患者中放射性坏死16%、出血32%、记忆缺陷19%。

核心结论

  • WBRT仍是控制MBM颅内疾病的有效策略,治疗相关毒性如病灶内出血、坏死或神经认知副作用有限。

研究设计与样本

  • 单中心回顾性数据库分析,纳入2000—2018年诊断为MBM并接受WBRT(可联合其他全身治疗)的患者,最终纳入63例。

主要发现

  • 69%的患者在WBRT时已有5个或以上脑转移灶,68%存在颅外疾病;中位WBRT剂量为30 Gy/10次,中位随访4.0个月。
  • 中位OS为7.0个月,中位PFS为2.2个月,中位远处失败无生存(DFFS)为6.1个月,中位局部失败无生存(LFFS)为4.9个月。
  • 体能状态在单因素和多因素分析中均与OS相关;BRAF抑制剂是唯一在单因素分析中显著影响OS的全身治疗(HR 0.24,95%CI 0.07-0.79,p=0.019),该效应在多因素分析中仍存在。
  • WBRT后病灶内出血在单因素和多因素分析中均降低DFFS;有治疗后脑影像的患者中放射性坏死率16%、出血率32%、记忆缺陷率19%。

关键数值与推荐

  • 中位WBRT剂量为30 Gy/10次;中位随访4.0个月;BRAF抑制剂与OS相关(HR 0.24,95%CI 0.07-0.79,p=0.019)。

临床怎么用

  • 对于多发性MBM患者,WBRT可作为控制颅内疾病的治疗选择,并应结合体能状态与BRAF抑制剂等全身治疗综合评估。
  • 治疗后需关注病灶内出血、放射性坏死和记忆缺陷等毒性并随访脑影像。

局限性

  • 单中心回顾性研究,样本量63例,中位随访仅4.0个月,部分患者缺乏治疗后脑影像评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of melanoma with brain metastases (MBM) is increasingly complex, especially given recent improvements in targeted agents, immunotherapy, and radiotherapy. Whole brain radiation therapy (WBRT) is a longstanding radiotherapy technique for which reported patient outcomes and experiences are limited. We sought to report our institutional outcomes for MBM patients receiving WBRT and assess whether other clinical factors impact prognosis. METHODS: A retrospective review of a single institution database was performed. Patients diagnosed with MBM from 2000 to 2018 treated with WBRT, with or without other systemic treatments, were included. Post-WBRT brain MRI scans were assessed at timed intervals for radiographic response. Clinical and treatment variables associated with overall survival (OS), distant failure-free survival (DFFS), local failure-free survival (LFFS), and progression-free survival (PFS) were assessed. Data on radiation-induced side effects, including radionecrosis, hemorrhage, and memory deficits, was also captured. RESULTS: 63 patients with MBM were ultimately included in our study. 69% of patients had 5 or more brain metastases at the time of WBRT, and 68% had extracranial disease. The median dose of WBRT was 30 Gy over 10 fractions. Median follow-up was 4.0 months. Patients receiving WBRT had a median OS of 7.0 months, median PFS of 2.2 months, median DFFS of 6.1 months, and median LFFS of 4.9 months. Performance status correlated with OS on both univariate and multivariable analysis. BRAF inhibitor was the only systemic therapy to significantly impact OS on univariate analysis (HR 0.24, 95% CI 0.07-0.79, p = 0.019), and this effect extended to multivariable analysis as well. Post-WBRT intralesional hemorrhage decreased DFFS on both univariate and multivariable analysis. Of patients with post-treatment brain scans available, there was a 16% rate of radionecrosis, 32% rate of hemorrhage, and 19% rate of memory deficits. CONCLUSIONS: Outcomes for MBM patients receiving WBRT indicate that WBRT remains an effective treatment strategy to control intracranial disease. Treatment-related toxicities such as intralesional hemorrhage, necrosis, or neurocognitive side effects are limited. With continued innovations in WBRT technique and systemic therapy development, MBM outcomes may continue to improve. Further trials should evaluate the role of WBRT in the modern context.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jiang C, Kleber TJ, Switchenko JM, et al. Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases. Radiat Oncol. 2021. PMID: 33557890. doi:10.1186/s13014-021-01754-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。